Sierra Oncology is having a very good year.
On Wednesday, the small U.S. drugmaker said it would be acquired by British pharma giant GlaxosmithKline for $1.9 billion. The deal was struck three months after Sierra’s lead drug, a treatment for the blood cancer myelofibrosis, succeeded in a late-stage clinical trial.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
